Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism

Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen. Clinical trials investigating the utility of adding fulvestrant to other therapeutics have...

Descripción completa

Detalles Bibliográficos
Autores principales: Edavana, Vineetha K, Penney, Rosalind B, Yao-Borengasser, Aiwei, Williams, Suzanne, Rogers, Lora, Dhakal, Ishwori B, Kadlubar, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841332/
https://www.ncbi.nlm.nih.gov/pubmed/24298433
http://dx.doi.org/10.1186/2193-1801-2-620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841332/
https://www.ncbi.nlm.nih.gov/pubmed/24298433
http://dx.doi.org/10.1186/2193-1801-2-620

Ejemplares similares